Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

48.53 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 48.53
Bid (Size) 48.44 (1)
Ask (Size) 48.50 (1)
Prev. Close 48.53
Today's Range 48.53 - 48.53
52wk Range 39.35 - 63.30
Shares Outstanding 2,222,113,553
Dividend Yield 5.11%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stay informed with the top movers within the S&P500 index on Wednesday.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Wednesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill

Performance

YTD
-14.54%
-14.54%
1 Month
-20.51%
-20.51%
3 Month
-14.99%
-14.99%
6 Month
-8.54%
-8.54%
1 Year
-0.94%
-0.94%

More News

Read More
What's going on in today's pre-market session: S&P500 movers
Via Chartmill
Tesla To $303? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Via Benzinga
Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect
Via StockStory
Bristol Myers Squibb Stock Slides After-Hours As Schizophrenia Trial Misses Goal, But Retail's Buying The Dip
Via Stocktwits
Topics Intellectual Property
Exposures Intellectual Property
Stay updated with the S&P500 stocks that are on the move in today's after-hours session.
Via Chartmill
Beyond The Numbers: 7 Analysts Discuss Bristol-Myers Squibb Stock
Via Benzinga
Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test
Via Investor's Business Daily
Exposures Product Safety
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach
Via Benzinga
Exposures Product Safety
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
From Bristol Myers Squibb
Via Business Wire
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Via Benzinga
Topics Government
Exposures Political
Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?
Via Benzinga
Which S&P500 stocks are moving on Tuesday?
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks
Via Chartmill
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It
Via Investor's Business Daily
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
From Bristol Myers Squibb
Via Business Wire
These Large-Cap Stocks With China And EU Exposure Got Crushed In The One Of The Most Volatile Trading Week (Apr 7-Apr 11): Are These In Your Portfolio?
Via Benzinga
Topics World Trade
Exposures Tariff
Why BRISTOL-MYERS SQUIBB CO (NYSE:BMY) qualifies as a good dividend investing stock.
Via Chartmill
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.